Bf 844 Compound Combination Therapy for BRCA-Mutated Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for various types of cancer, including colorectal, glioblastoma, lung, ovarian, pancreatic, cervical, prostate, breast, gastric, head and neck, liver, melanoma, lymphopoietic, hematopoietic, soft tissue sarcoma, and osteosarcoma, lack effective methods, particularly for those with BRCA mutations, and there is a need for new approaches to treat, prevent, or reduce the risk of these cancers and inflammatory or autoimmune diseases.
Innovation Solution
The use of specific compounds, such as those of Formulae I to XV, or their pharmaceutically acceptable salts, administered in combination with anti-cancer therapies like chemotherapy, targeted therapy, hormone therapy, immunotherapy, or stem cell therapy, to treat and prevent these cancers and inflammatory or autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-cancer therapies are used, then treatment is provided for common cancers, but they lack effectiveness for cancers with BRCA mutations and various other cancer types
Solution Approach 1:
The compound Bf 844 is designed to have universal anti-cancer activity across multiple cancer types including BRCA-mutated cancers, colorectal cancer, glioblastoma, lung cancer, ovarian cancer, pancreatic cancer, and others. The compound serves multiple therapeutic functions simultaneously, addressing both BRCA-mutated and non-BRCA cancer types with a single agent, thereby improving versatility without sacrificing reliability
Solution Approach 2:
The invention changes the chemical parameter by introducing a novel compound structure (Bf 844) with specific molecular characteristics that enable it to interact with different cancer pathways. This structural parameter change allows the compound to effectively target cancers with BRCA mutations while also being effective against other cancer types that respond poorly to existing therapies
2Reliability
If new compounds are developed to treat BRCA-mutated cancers, then effectiveness for specific cancer types improves, but the complexity of treatment regimens increases
Solution Approach 1:
Bf 844 serves as a universal anti-cancer agent that can be applied across multiple cancer types and mutation profiles. By using a single compound that addresses both BRCA-mutated and other cancer types, the treatment regimen complexity is reduced compared to using different specialized therapies for each cancer type
Solution Approach 2:
The compound Bf 844 merges the therapeutic capabilities needed for treating BRCA-mutated cancers with effectiveness against other cancer types into a single agent. This consolidation eliminates the need for complex multi-drug regimens or separate treatment protocols for different cancer types, thereby reducing overall treatment complexity
Data Source
AI summary
The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.